Related Experiment Video

Updated: May 13, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Evolving therapeutic targets in renal cell carcinoma

Eric A Singer1, Gopal N Gupta, Daniel Marchalik

  • 1Section of Urologic Oncology, The Cancer Institute of New Jersey and UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.

Current Opinion in Oncology
|March 5, 2013
PubMed
Abstract

Insights

Recent advancements in advanced renal cell carcinoma (RCC) treatment focus on targeted therapies and combination strategies. Further research is needed to optimize drug selection and sequencing for specific kidney cancer subtypes.

Area of Science:

  • Oncology
  • Genitourinary Cancer
  • Medical Genetics

Background:

  • Advanced renal cell carcinoma (RCC) treatment landscape is evolving with new targeted agents.
  • Understanding the molecular and genetic basis of RCC subtypes is crucial for personalized medicine.

Purpose of the Study:

  • To review recent developments in advanced RCC treatment, focusing on data from the past year.
  • To discuss the genetics and molecular biology of kidney cancer subtypes for rational drug development.

Main Methods:

  • Review of recent scientific literature on advanced renal cell carcinoma (RCC) treatment.
  • Analysis of genomic and metabolic alterations in various kidney cancer histologic subtypes.

Main Results:

  • Targeting vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways remains foundational for metastatic kidney cancer.
  • Emphasis on target selectivity and affinity to reduce toxicity in clear cell RCC.
  • Combination strategies and histology-specific protocols for nonclear cell RCC are under investigation, with no specific drug approvals yet.

Conclusions:

  • The number of approved treatments for advanced RCC is increasing.
  • Further research is required to determine optimal drug choices, combinations, and sequences for each RCC subtype.

More Related Videos

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...